A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
Clinical trial NCT05078931 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05078931
- Sponsor
- Shanghai Chest Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-27
- Primary completion
- 2025-12-30
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.